| Preview | Issue Date | Title | Author(s) |
| 22-Nov-2023 | A Phase 1 Study with the Novel B-Cell Lymphoma 2 (Bcl-2) Inhibitor Bgb-11417 As Monotherapy or in Combination with Zanubrutinib (ZANU) in Patients (Pts) with CLL/SLL: Preliminary Data. | Cheah C.Y.; Tam C.S.; Lasica M.; Verner E.; Browett P.J.; Anderson M.A.; Hilger J.; Fang Y.; Simpson D.; Opat S. |
| 10-Sep-2022 | A phase 1 study with the novel b-cell lymphoma 2 (bcl2) inhibitor bgb-11417 as monotherapy or in combination with zanubrutinib (zanu) in patients (pts) with b-cell malignancies: preliminary data. | Opat S. ; Cheah C.Y.; Lasica M.; Verner E.; Browett P.J.; Chan H.; Soumerai J.D.; Barca E.G.; Hilger J.; Fang Y.; Huang J.; Simpson D.; Tam C.S. |
| 14-Aug-2017 | Bruton's tyrosine kinase (BTK) inhibitor BGB-3111 demonstrates high very good partial response (VGPR) rate in patients with Waldenstrom macroglobulinemia (WM). | Seymour J.F.; Trotman J.; Opat S. ; Marlton P.; Gottlieb D.; Simpson D.; Cull G.; Ritchie D.; Verner E.; Ratnasingam S.; Anderson M.; Wood P. ; Wang L. ; Xue L.; Hedrick E.; Huang J.; Hilger J.; Tam C.S.; Roberts A.W. |
| 26-Sep-2022 | CLL-118 A Phase 1 Study With the Novel B-Cell Lymphoma 2 Inhibitor BGB-11417 as Monotherapy or in Combination With Zanubrutinib in Patients With B-Cell Malignancies: Preliminary Data. | Soumerai J.D.; Opat S. ; Cheah C.Y.; Lasica M.; Verner E.; Browett P.J.; Chan H.; Barca E.G.; Hilger J.; Fang Y.; Simpson D.; Tam C.S. |
| 22-Feb-2024 | Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study. | Tam C.S.; Anderson M.A.; Lasica M.; Verner E.; Opat S.S.; Ma S.; Weinkove R.; Cordoba R.; Soumerai J.; Ghia P.; Leitch S.; Hilger J.; Fang Y.; Simpson D.; Guo H.; Cheah C.Y. |
| 14-Aug-2017 | High overall response rate with the BTK inhibitor BGB-3111 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma: An update on safety and activity. | Tam C.S.; Wang L. ; Xue L.; Hilger J.; Huang J.; Hedrick E.; Roberts A.W.; Seymour J.F.; Opat S. ; Cull G.; Trotman J.; Gottlieb D.; Simpson D.; Marlton P.; Anderson M.; Ku M.; Ritchie D.S.; Ratnasingam S.; Augustson B.; Kim W. |
| 17-Jan-2019 | Improved depth of response with increased follow-up for patients (PTS) with waldenstrom macroglobulinemia (WM) treated with bruton's tyrosine kinase (BTK) inhibitor zanubrutinib. | Opat S. ; Wood P. ; Hedrick E.; Huang J.; Ro S.; Hilger J.; Seymour J.F.; Roberts A.W.; Trotman J.; Tam C.S.; Marlton P.; Gottlieb D.; Simpson D.; Cull G.; Ritchie D.; Verner E.; Munoz J.; Ratnasingam S.; Anderson M.A. |
| 22-Feb-2024 | Monotherapy with Second-Generation BCL2 Inhibitor Sonrotoclax (BGB-11417) Is Well Tolerated with High Response Rates in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Data from an Ongoing Phase 1 Study. | Tedeschi A.; Cheah C.Y.; Opat S.S.; Verner E.; Magnano L.; Epperla N.; Hilger J.; Fang Y.; Simpson D.; Guo H.; Anderson M.A. |
| 17-Jan-2019 | Pooled analysis of safety data from zanubrutinib (BGB-3111) monotherapy studies in hematologic malignancies. | Opat S. ; Roberts A.W.; Cull G.; Tam C.S.; Trotman J.; Simpson D.; Ritchie D.; Verner E.; Ratnasingam S.; Anderson M.A.; Wood P. ; Seymour J.F.; Zhu J.; Li J.; Marlton P.; Gottlieb D.; Lin L.; Ro S.; Hilger J.; Wang A.; Xu X.; Ji M. |
| 27-May-2022 | Preliminary safety and efficacy data from patients (PTS) with relapsed/refractory (r/r) b-cell malignancies treated with the novel b-cell lymphoma 2 (bcl2) inhibitor bgb-11417 in monotherapy or in combination with zanubrutinib. | Ghia P.; Tam C.; Verner E.; Lasica M.; Arbelaez A.; Browett P.; Soumerai J.; Hilger J.; Fang Y.; Huang J.; Simpson D.; Opat S. ; Cheah C. |
| 28-Dec-2021 | Preliminary Safety and Efficacy Data from Patients (Pts) with Relapsed/Refractory (R/R) B-Cell Malignancies Treated with the Novel B-Cell Lymphoma 2 (BCL2) Inhibitor BGB-11417 in Monotherapy or in Combination with Zanubrutinib. | Tam C.S.; Verner E.; Lasica M.; Arbelaez A.; Browett P.J.; Soumerai J.D.; Hilger J.; Fang Y.; Huang J.; Simpson D.; Opat S. ; Cheah C.Y.Y. |
| 1-Sep-2021 | Preliminary safety data from patients (PTS) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417. [HemaSphere] | Cheah C.Y.; Verner E.; Tam C.S.; Hilger J.; Gao Y.; Huang J.; Simpson D.; Opat S. |
| 25-Jun-2021 | Preliminary safety data from patients (pts) with relapsed/refractory (R/R) B-cell malignancies treated with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417. [Hematological Oncology] | Cheah C.Y.; Verner E.; Tam C.S.; Hilger J.; Gao Y.; Huang J.; Simpson D.; Opat S. |
| 13-Nov-2024 | Results from the phase 1 study of the novel bcl2 inhibitor sonrotoclax (SONRO; bgb-11417) in combination with zanubrutinib (ZANU) for relapsed/refractory (R/R) cll/sll show deep and durable responses. | Stilgenbauer S.; Opat S. ; Anderson M.A.; Tedeschi A.; Verner E.; Lasica M.; Arbelaez A.; Browett P.; Leitch S.; Gonzalez-Barca E.; Shadman M.; Hou J.-Z.; Eradat H.; Ma S.; Westerman D.; Fang Y.; Hilger J.; Patel S.; Ding W.; Guo H.; Tam C.S. |
| 31-Jan-2018 | Safety and activity of the highly specific BTK inhibitor BGB-3111 in combination with the PD-1 inhibitor BGB-A317 in patients with B-cell lymphoid malignancies. | Opat S. ; Tam C.S.; Huang J.; Cull G.; Trotman J.; Ro S.; Feng S.; Zhang X.; Hilger J. |
| 25-Jan-2018 | Safety and activity of the highly specific BTK inhibitor bgb-3111 in patients with indolent and aggressive non hodgkin's lymphoma. | Tam C.S.; Lee W.-S.; Marlton P.; Gottlieb D.; Wang L. ; Huang J.; Hilger J.; Xue L.; Ro S.; Munoz J.; Johnston P.B.; Cull G.; Wang M.; Simpson D.; Kim W.S.; Opat S. |
| 1-Mar-2019 | Updated safety and activity of the investigational bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) in patients with mantle cell lymphoma. | Huang J.; Hilger J.; Novotny W.; Trotman J.; Tam C.S.; Wang M.; Simpson D.; Opat S. ; Cull G.; Munoz J.; Phillips T.J.; Kim W.-S. |
| 30-Mar-2023 | Zanubrutinib, Alone and in Combination with Tislelizumab, for the Treatment of Richter Transformation of Chronic Lymphocytic Leukemia. | Tam C.; Munoz J.; Cull G.; Opat S. ; Allewelt H.; Zhang X.; Stern J.C.; Hilger J.; By K.; Cohen A.; Tedeschi A. |
